The global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period. The prostate gland (the prostate) is an organ of the male reproductive system. The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer. Benign prostatic hyperplasia (BPH) is defined as a medical condition affecting men. It involves the non-cancerous enlargement of the prostate gland. While BPH rarely shows symptoms before the age of 40, the risk of contracting BPH increases with age. The condition affects nearly 50% of men between the ages of 51 and 60 and up to 90% of men older than 80. Treatment measures such as medications and surgery have been used for patients with BPH.
Prostate Cancerto hold thelargestsegmentof the market Based on disease indication, the prostate health market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis.In 2020, prostate cancer accounted for the largest share in the prostate health market.
Typically, hormone therapy is considered an effective option as the first line of treatment for prostate cancer.Cancer vaccines, radiopharmaceutical agents, secondary hormone therapies, or chemotherapies follow hormonal therapy as treatment options.
Cancerous cells are found to be developing a resistance to these therapies after some months, as a result of which immunotherapies are expected to be adopted widely for the treatment of prostate cancer in the near future.
The US to dominate theprostate health market in North America The prostate health market is segmented into five six regions—North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.North America has been among the frontrunners in developing prostate health therapiesin the healthcare industry.
The market growth in the US (a major contributor to the North American prostate health market) can be mainly attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong healthcare infrastructure, research funding, and product launches have accelerated the growth of this market.
Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35% • By Designation:Director-level – 30%, C-level – 20%, and Others – 50% • By Region: North America - 33%, Europe – 24%, APAC –27%, Rest of the World –16% Some of the prominent players operating in the prostate healthmarket are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players.
Research Coverage This report studies the prostate health market based on type, mode of purchase, and application, and region.The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth.
It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to two main geographies – source and destination.
Key Benefits of Buying the Report This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
Our reports have been used by over 10K customers, including:
The global rotator cuff injury treatment market is projected to reach USD 1,244 million by 2026 from USD 989 million in 2021, at a CAGR of 4.7% during the forecast period”. The key factors fueling the growth of this market include an increase in sports related shoulder injuries, technological advancements in arthroscopic surgical devices,...
The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to grow at a CAGR of 47.1% from 2021 to 2028. Major factors driving the non-alcoholic steatohepatitis (NASH) market growth include the rising prevalence of NASH and increasing initiatives...
The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development &...
The skincare treatment devices market is projected to reach US$ 23,378.96 million by 2028 from US$ 10,898.26 million in 2021; it is estimated to grow at a CAGR of 11.5% during 2021-2028. Increasing prevalence of skin disorders and rising awareness about beauty devices, along with increasing new product launches and rising developments...
The hyperhidrosis treatment market studied is anticipated to grow with a CAGR of 6.2% during the forecast period. The major factors attributing to the growth of the hyperhidrosis treatment market are a rise in the prevalence of secondary hyperhidrosis conditions and an increase in investments by players for research and development. According...
The global digital therapeutics market is expected to grow from US$ 4,226.94 million in 2021 to US$ 18,061.79 million by 2028; it is estimated to grow at a CAGR of 23.1% from 2021 to 2028. The increasing prevalence of chronic diseases, the growing need to reduce healthcare costs, and partnerships and collaborations by companies fuel...
350 pages •
By Roots Analysis Private Ltd.
• Mar 2022
INTRODUCTION The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. The project was undertaken to understand the concept of core human microbiome and its compatibility with the host physiology. Further, with the significant advancements in the sequencing...
The Global Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period. Benign prostatic hyperplasia (BPH) is a benign swelling of the prostate gland that is not malignant. Benign prostatic hypertrophy or benign prostatic blockages...
The global RNAi therapeutics market is expected to record a value of US$1.15 billion in 2026, progressing at a CAGR of 10.19%, over the period 2022-2026. Factors such as rising utilization in oncology pharmaceuticals, accelerating growth rates of infectious diseases, enlarging geriatric population, increasing prevalence of neurodegenerative...
192 pages •
By The Business Research Company
• Feb 2022
Alpha Mannosidosis Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global alpha mannosidosis market as it emerges from the COVID 19 shut down. Description: Where is the largest...
Gross Domestic Product Per Capita
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.